This article is more than 5 years old. Information may no longer be current.
VIDEO: Entospletinib shows promise for advanced lymphoma
Click Here to Manage Email Alerts
CHICAGO — Entospletinib appeared safe for patients with relapsed or refractory lymphoplasmacytoid lymphoma, according to study results presented at the ASCO Annual Meeting.
Kathryn S. Kolibaba, MD, who practices with the U.S. Oncology Network at Compass Oncology, and colleagues conducted a phase 2 trial designed to evaluate the safety and efficacy of entospletinib (GS-9973, CGI Pharmaceuticals) — an orally bioavailable, selective inhibitor of spleen tyrosine kinase — in 17 patients with lymphoplasmacytoid lymphoma.
Entospletinib demonstrated clinical benefit but not sufficient to pursue the drug as single-agent therapy.
However, the drug’s safety profile makes it a potentially valuable agent for combination use, Kolibaba told HemOnc Today.
Adverse events appeared limited to low-grade fatigue, nausea and diarrhea.
“In all of the cohort, patients were able to live full lives, travel and really do well in terms of tolerability for the drug,” Kolibaba said. – by Kristie L. Kahl
Disclosure: Kolibaba reports no relevant financial disclosures.